Learning Ecosystems for Accelerating Patient-Centered, Sustainable Innovation
The LEAPS Project's goal is to design and pilot a next generation innovation ecosystem to deliver more value faster to patients from new medicines, in ways that work for all stakeholders. LEAPS focuses on connecting the siloes of drug development (R&D) and delivery (patient care) through transformational system innovations, such as platform clinical trials, and a “Learning Engine” comprised of an end-to-end distributed evidence generation infrastructure.
LEAPS will leverage proven NEWDIGS methods and tools for collaborative systems engineering involving patients, providers, payers, biotechnology and pharmaceutical companies, information technology firms, regulators, payers, public health officials, and academic researchers.
LEAPS design launched in early 2018. Target diseases under consideration for the pilot are rheumatoid arthritis, type 2 diabetes, Alzheimer’s Disease, and opioid addiction. Objectives beyond improving patient outcomes include:
- Enhancing the value of the growing array of disparate data and evidence from electronic medical records and insurance claims, to mobile apps and longitudinal patient/disease registries.
- Accelerating healthcare insights from data analytics tools such as artificial intelligence, machine learning, and blockchain technologies.
- Establish community hospitals and clinics as key elements of the broader innovation ecosystem.
Elements of the strategic vision for LEAPS were explored at the Next Wave Forum, http://nextwave.mit.edu hosted by MIT NEWDIGS on December 12-13, 2017 in Cambridge, Massachusetts. The event included keynote speakers Janet Woodcock (FDA), Hans-Georg Eichler (European Medicines Agency), Trent Haywood (Blue Cross Blue Shield), Donald Berwick (former Centers for Medicare and Medicaid, and Institute for Healthcare Improvement); MIT’s Sandy Pentland, Jonathan Gruber, and Michael Cusumano.